These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 24886434)

  • 1. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.
    Abubaker K; Luwor RB; Escalona R; McNally O; Quinn MA; Thompson EW; Findlay JK; Ahmed N
    Front Oncol; 2014; 4():75. PubMed ID: 24782986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
    Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
    Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
    Doheny D; Sirkisoon S; Carpenter RL; Aguayo NR; Regua AT; Anguelov M; Manore SG; Arrigo A; Jalboush SA; Wong GL; Yu Y; Wagner CJ; Chan M; Ruiz J; Thomas A; Strowd R; Lin J; Lo HW
    Oncogene; 2020 Oct; 39(42):6589-6605. PubMed ID: 32929154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
    Escalona RM; Bilandzic M; Western P; Kadife E; Kannourakis G; Findlay JK; Ahmed N
    BMC Cancer; 2020 Oct; 20(1):960. PubMed ID: 33023532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
    Xu Y; Zhang J; Wu J; Zhong S; Li H
    Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
    Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV
    Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
    Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
    Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo.
    Kandala PK; Srivastava SK
    Drug Discov Ther; 2012 Apr; 6(2):94-101. PubMed ID: 22622019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin‑resistant SKOV3/DDP ovarian cancer cells.
    Zhong Y; Le F; Cheng J; Luo C; Zhang X; Wu X; Xu F; Zuo Q; Tan B
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
    Liu T; Li A; Xu Y; Xin Y
    Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
    Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
    Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
    Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
    Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer.
    Jin J; Guo Q; Xie J; Jin D; Zhu Y
    Pathol Oncol Res; 2019 Apr; 25(2):769-775. PubMed ID: 30706361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.
    Chan E; Luwor R; Burns C; Kannourakis G; Findlay JK; Ahmed N
    Oncotarget; 2018 Mar; 9(24):16599-16618. PubMed ID: 29682172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis.
    Burgos-Ojeda D; Wu R; McLean K; Chen YC; Talpaz M; Yoon E; Cho KR; Buckanovich RJ
    Mol Cancer Ther; 2015 Jul; 14(7):1717-27. PubMed ID: 25969154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.